Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive eating behaviors. No effective therapy is currently available. At a symposium held during the recent FENS Forum in Barcelona, several leading researchers with decades of experience in AN presented findings that further strengthen the growing body of evidence supporting the disorder’s metabolic component. Read More
In a recent study, scientists from Stanford University and collaborators aimed to develop a platform for specific tumor-immune cell targeting, focusing on tumor-associated macrophages (TAMs), with the eventual goal of interfacing with existing immune checkpoint inhibitor technologies. Read More
Niagen Bioscience Inc.’s proprietary lead small-molecule drug candidate, NB-4168, has been awarded European orphan drug designation and U.S. rare pediatric disease designation for the treatment of ataxia telangiectasia. Read More
Human cytomegalovirus (CMV) is a clinical challenge in infants and immunocompromised individuals, since no licensed vaccine exists. Vaccine development is complex due to several factors, including viral latency, genomic complexity and immune evasion, among others. Evaxion A/S recently presented data on its proprietary AI-immunology platform used to create the EVX-V1 vaccine for CMV infection. Read More
Duchenne muscular dystrophy (DMD) is a progressive, genetic (X-linked recessive) neuromuscular disorder caused by mutations to the DMD gene, resulting in the dysfunction or absence of the dystrophin protein. In DMD, muscle regeneration initially depends on the proliferation and differentiation of muscle satellite cells (MuSCs), but their regenerative capacity progressively declines, making repair inefficient and contributing to muscle dysfunction. Read More
Despite multiple analgesics on the market, current therapeutics often fail at achieving complete pain relief and are usually tied to undesired adverse effects. Recent studies have pointed to adenosine A3 receptor (A3AR) as a promising target for pain management. Read More
Nutshell Therapeutics Inc. has synthesized new nitrogen-containing heteroaryl compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer. Read More
Wuhan Createrna Science and Technology Co. Ltd. has reported new complement factor D (CFD) inhibitors potentially useful for the treatment of cardiovascular, immunological, eye, genitourinary, renal, respiratory, neurological disorders and hematological diseases. Read More
Aggregated α-synuclein (α-Syn) is encoded by the SNCA gene and is one of the key pathological proteins linked to Parkinson’s disease. However, it is still not clear whether or not α-Syn originating in the periphery has a role in the pathology in the brain. Read More
Researchers from the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, Nanyang Technological University and the University of Montpellier have patented new Mycobacterium sp. ATP synthase (F0F1 ATPase) inhibitors potentially useful for the treatment of nontuberculous mycobacterial infections. Read More
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed new compounds acting as lipid-lowering agents and gluconeogenesis inhibitors potentially useful for the treatment of metabolic diseases. Read More
A joint Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details new S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors potentially useful for the treatment of cancer. Read More
